scholarly journals Carboxypeptidase M Expressed by Human Bone Marrow Cells Cleaves the C-Terminal Lysine of Stromal Cell-Derived Factor-1α: Another Player in Hematopoietic Stem/Progenitor Cell Mobilization?

Stem Cells ◽  
2008 ◽  
Vol 26 (5) ◽  
pp. 1211-1220 ◽  
Author(s):  
Leah Marquez-Curtis ◽  
Ali Jalili ◽  
Kathleen Deiteren ◽  
Neeta Shirvaikar ◽  
Anne-Marie Lambeir ◽  
...  
Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 351-351
Author(s):  
Leah A. Marquez-Curtis ◽  
Kathleen Deiteren ◽  
Lambeir Anne-Marie ◽  
Ali Jalili ◽  
Neeta Shirvaikar ◽  
...  

Abstract Carboxypeptidase M (CPM) is a zinc-dependent phospho-inositol-anchored protease that cleaves carboxy-terminal basic residues such as arginine or lysine from peptides. CPM is primarily membrane-bound, glycosylated, has a neutral pH optimum, and occurs in placental microvilli, seminal plasma, amniotic fluid, peripheral nerves, alveolar epithelial cells and macrophages. In this work, we examined whether CPM is expressed in various cells in the bone marrow (BM) including hematopoietic stem/progenitor cells (HSPC) and whether it plays a role in the stromal cell-derived factor (SDF)-1α-directed mobilization of HSPC from the BM) to peripheral blood (PB). SDF-1α produced by BM stromal cells retains HSPC in the BM and its proteolytic degradation results in mobilization. When exposed to serum, full-length SDF-1α (1–68) undergoes rapid cleavage of the C-terminal lysine yielding SDF-1α (1–67) which is then cleaved at the N-terminus by matrix metalloproteinases, CD26 and serine proteases or elastases, generating a truncated form of SDF-1α (3–67) with reduced chemoattractant activity. In this work, we present the first evidence that CPM can cleave the C-terminal lysine and furthermore reduces the ability of SDF-1α (1–67) to chemoattract HSPC. We found that CPM (i) is expressed by BM CD34+ cells strongly and weakly by PB CD34+ cells, mononuclear cells, neutrophils, mesenchymal stem cells and leukemic cell lines (THP-1 monocytic, KG-1 acute myeloid) by RT-PCR and flow cytometry; (ii) occurs on the cell surface of these cells and co-localizes with the SDF-1α receptor CXCR4 (by confocal microscopy); and (iii) is present on myeloid and megakaryocytic precursor cells, but not erythroid cells. G-CSF, the most commonly used agent for mobilization, slightly increased (1.2-fold) the expression of CPM in CD34+ cells at the gene level. Moreover, because in vivo SDF-1α (i.e., in serum) already lacks the C-terminal lysine, we used biologically active synthetic SDF-1α (1-67), and after treatment with CPM observed a significantly reduced chemoattraction for CD34+ cells. Furthermore, prolonged exposure of SDF-1α (over 24 h) to CPM completely obliterated its chemotactic activity but pre-incubating CPM with the peptidase inhibitor (DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid) restored it. Because CPM is localized on the plasma membrane, it is ideally situated to modulate the activity of this chemokine. As it has been suggested that the C-terminal lysine of SDF-1α binds with heparin on the cell surface, preserving the activity of SDF-1α, we propose that CPM cleavage of lysine could release the SDF-1α from the cell surface and expose it to further proteolytic degradation, resulting in the mobilization of HSPC to the circulation. In conclusion, we present the first evidence that CPM cleaves the C-terminal lysine residue of SDF-1α, and that it is expressed by various cells in the BM microenvironment, which may facilitate HSPC mobilization; however, understanding the full biological functions of this enzyme requires further investigation.


Blood ◽  
2011 ◽  
Vol 118 (15) ◽  
pp. 4093-4101 ◽  
Author(s):  
Yiyue Zhang ◽  
Hao Jin ◽  
Li Li ◽  
F. Xiao-Feng Qin ◽  
Zilong Wen

Abstract The establishment of the HSC pool in vertebrates depends not only on the formation and the propagation of these stem cells but also on their proper trafficking among the defined hematopoietic organs. However, the physiologic mechanisms that regulate HSC mobilization remain elusive. Through analysis of the zebrafish cmyb mutant cmybhkz3, we show that the suppression of cMyb function abrogates larval and adult hematopoiesis, with concomitant accumulation of hematopoietic stem/progenitor cells (HSPCs) in their birthplace, the ventral wall of the dorsal aorta (VDA). Cell tracking and time-lapse recording reveal that the accumulation of HSPCs in cmybhkz3 mutants is caused by the impairment of HSPC egression from the VDA. Further analysis demonstrates that the HSPC migratory defects in cmybhkz3 mutants are at least partly because of adversely elevated levels of chemokine stromal cell-derived factor 1a (Sdf1a). Our study reveals that cMyb plays a hitherto unidentified role in dictating physiologic HSPC migration by modulating Sdf1a signaling.


Blood ◽  
1991 ◽  
Vol 78 (1) ◽  
pp. 30-37 ◽  
Author(s):  
LK Ashman ◽  
AC Cambareri ◽  
LB To ◽  
RJ Levinsky ◽  
CA Juttner

Abstract The c-kit proto-oncogene product is a member of the family of growth factor receptors with intrinsic tyrosine kinase activity. In the mouse c-kit maps to the W locus, which is known to be of central importance in hematopoiesis. Monoclonal antibody (MoAb) YB5.B8, which was raised against peripheral blood blast cells from a patient with acute myeloid leukemia (AML), was recently shown to bind to the extracellular domain of the c-kit product. This antibody does not bind detectably to normal peripheral blood cells and identifies a sub-group of AML patients with poor prognosis. We have used MoAb YB5.B8 to study the expression of c- kit by normal human bone marrow cells by immunofluorescence and flow cytometry, and to isolate multipotential and erythroid colony-forming cells. In a series of 11 normal adult bone marrow specimens, MoAb YB5.B8 bound to 4.0% +/- 1.8% of the cells in the low-density fraction. Dual-labeling experiments were performed with YB5.B8, and CD33, CD34, and CD10 MoAbs. Three populations of cells binding YB5.B8 could be identified based on their pattern of coexpression of the other markers; ie, YB5.B8+/CD34+/CD33-, YB5.B8+/CD34+/CD33+ and YB5.B8+/CD34+/CD33+. These populations had distinctive two-dimensional light scatter characteristics and are likely to correspond to precursor colony- forming cells, colony-forming cells, and maturing mast cells, respectively. No cells binding both YB5.B8 and an MoAb to the early lymphoid marker CD10 were found, implying that most early lymphoid cells do not express c-kit. MoAbs to the c-kit protein should prove valuable in multimarker studies of human hematopoietic stem and progenitor cells. Definition of a reference range of c-kit expression in normal human bone marrow will provide a sound basis for further studies of this marker in diagnosis and prognosis in AML.


Blood ◽  
1992 ◽  
Vol 79 (6) ◽  
pp. 1404-1412 ◽  
Author(s):  
EF Srour ◽  
ED Zanjani ◽  
JE Brandt ◽  
T Leemhuis ◽  
RA Briddell ◽  
...  

Abstract Sheep were transplanted in utero during early gestation with subpopulations of adult human bone marrow (BM) cells enriched for human progenitor and hematopoietic stem cells (HSC). Chimerism was documented in three of seven transplanted fetuses using monoclonal antibodies against human-specific hematopoietic cell lineages and/or cytogenetic analysis of BM and peripheral blood cells of recipients. Only chimeric sheep BM cells expressing CD45 (6.0% of total BM cells) formed human hematopoietic colonies in response to human recombinant cytokines as determined by cytogenetic analysis. Sorted CD45+ BM cells developed human T-cell colonies containing CD3+, CD4+, and CD8+ cells. DNA from chimeric BM cells obtained 3 months after birth displayed a finger printing pattern identical to that of DNA from the human donor of the HSC graft. These studies indicate that first trimester sheep fetuses are tolerant of adult human HSC grafts, thus permitting the creation of xenogeneic chimera expressing human myeloid and lymphoid lineages. The present findings also suggest that HSC grafts from immunologically competent, HLA-mismatched adult donors may be useful for correcting human genetic diseases in utero during early gestation.


Blood ◽  
2000 ◽  
Vol 95 (3) ◽  
pp. 769-775 ◽  
Author(s):  
Keiko Hodohara ◽  
Nobutaka Fujii ◽  
Naoki Yamamoto ◽  
Kenneth Kaushansky

Stromal cell-derived factor-1 (SDF-1) is a CXC chemokine that acts as a stimulator of pre-B lymphocyte cell growth and as a chemoattractant for T cells, monocytes, and hematopoietic stem cells. More recent studies also suggest that megakaryocytes migrate in response to SDF-1. Because genetic elimination of SDF-1 or its receptor lead to marrow aplasia, we investigated the effect of SDF-1 on megakaryocyte progenitors (colony-forming units-megakaryocyte [CFU-MK]). We report that SDF-1 augments the growth of CFU-MK from whole murine bone marrow cells when combined with thrombopoietin (TPO). The addition of SDF-1 to interleukin-3 (IL-3) or stem cell factor (SCF) had no effect. Specific antagonists for CXCR4 (the sole receptor for SDF-1), T22, and 1-9 (P2G) SDF-1 reduced megakaryocyte colony growth induced by TPO alone, suggesting that many culture systems contain endogenous levels of the chemokine that contributes to the TPO effect. To examine whether SDF-1 has direct effects on CFU-MK, we developed a new protocol to purify megakaryocyte progenitors. CFU-MK were highly enriched in CD41high c-kithigh cells generated from lineage-depleted TPO-primed marrow cells. Because the growth-promoting effects of SDF-1 were also observed when highly purified populations of CFU-MK were tested in serum-free cultures, these results suggest that SDF-1 directly promotes the proliferation of megakaryocytic progenitors in the presence of TPO, and in this way contributes to the favorable effects of the bone marrow microenvironment on megakaryocyte development.


Blood ◽  
1991 ◽  
Vol 78 (1) ◽  
pp. 30-37 ◽  
Author(s):  
LK Ashman ◽  
AC Cambareri ◽  
LB To ◽  
RJ Levinsky ◽  
CA Juttner

The c-kit proto-oncogene product is a member of the family of growth factor receptors with intrinsic tyrosine kinase activity. In the mouse c-kit maps to the W locus, which is known to be of central importance in hematopoiesis. Monoclonal antibody (MoAb) YB5.B8, which was raised against peripheral blood blast cells from a patient with acute myeloid leukemia (AML), was recently shown to bind to the extracellular domain of the c-kit product. This antibody does not bind detectably to normal peripheral blood cells and identifies a sub-group of AML patients with poor prognosis. We have used MoAb YB5.B8 to study the expression of c- kit by normal human bone marrow cells by immunofluorescence and flow cytometry, and to isolate multipotential and erythroid colony-forming cells. In a series of 11 normal adult bone marrow specimens, MoAb YB5.B8 bound to 4.0% +/- 1.8% of the cells in the low-density fraction. Dual-labeling experiments were performed with YB5.B8, and CD33, CD34, and CD10 MoAbs. Three populations of cells binding YB5.B8 could be identified based on their pattern of coexpression of the other markers; ie, YB5.B8+/CD34+/CD33-, YB5.B8+/CD34+/CD33+ and YB5.B8+/CD34+/CD33+. These populations had distinctive two-dimensional light scatter characteristics and are likely to correspond to precursor colony- forming cells, colony-forming cells, and maturing mast cells, respectively. No cells binding both YB5.B8 and an MoAb to the early lymphoid marker CD10 were found, implying that most early lymphoid cells do not express c-kit. MoAbs to the c-kit protein should prove valuable in multimarker studies of human hematopoietic stem and progenitor cells. Definition of a reference range of c-kit expression in normal human bone marrow will provide a sound basis for further studies of this marker in diagnosis and prognosis in AML.


Blood ◽  
1992 ◽  
Vol 79 (6) ◽  
pp. 1404-1412 ◽  
Author(s):  
EF Srour ◽  
ED Zanjani ◽  
JE Brandt ◽  
T Leemhuis ◽  
RA Briddell ◽  
...  

Sheep were transplanted in utero during early gestation with subpopulations of adult human bone marrow (BM) cells enriched for human progenitor and hematopoietic stem cells (HSC). Chimerism was documented in three of seven transplanted fetuses using monoclonal antibodies against human-specific hematopoietic cell lineages and/or cytogenetic analysis of BM and peripheral blood cells of recipients. Only chimeric sheep BM cells expressing CD45 (6.0% of total BM cells) formed human hematopoietic colonies in response to human recombinant cytokines as determined by cytogenetic analysis. Sorted CD45+ BM cells developed human T-cell colonies containing CD3+, CD4+, and CD8+ cells. DNA from chimeric BM cells obtained 3 months after birth displayed a finger printing pattern identical to that of DNA from the human donor of the HSC graft. These studies indicate that first trimester sheep fetuses are tolerant of adult human HSC grafts, thus permitting the creation of xenogeneic chimera expressing human myeloid and lymphoid lineages. The present findings also suggest that HSC grafts from immunologically competent, HLA-mismatched adult donors may be useful for correcting human genetic diseases in utero during early gestation.


Sign in / Sign up

Export Citation Format

Share Document